Cargando…
CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas
Cyclin-Dependent Kinases (CDKs) are well-known reliable targets for cancer treatment being often deregulated. Among them, since the transcription-associated CDK9 represents the sentry of cell transcriptional homeostasis, it can be a valuable target for managing cancers in which the transcriptional m...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438590/ https://www.ncbi.nlm.nih.gov/pubmed/32903585 http://dx.doi.org/10.3389/fphar.2020.01230 |
_version_ | 1783572823407591424 |
---|---|
author | Cassandri, Matteo Fioravanti, Rossella Pomella, Silvia Valente, Sergio Rotili, Dante Del Baldo, Giada De Angelis, Biagio Rota, Rossella Mai, Antonello |
author_facet | Cassandri, Matteo Fioravanti, Rossella Pomella, Silvia Valente, Sergio Rotili, Dante Del Baldo, Giada De Angelis, Biagio Rota, Rossella Mai, Antonello |
author_sort | Cassandri, Matteo |
collection | PubMed |
description | Cyclin-Dependent Kinases (CDKs) are well-known reliable targets for cancer treatment being often deregulated. Among them, since the transcription-associated CDK9 represents the sentry of cell transcriptional homeostasis, it can be a valuable target for managing cancers in which the transcriptional machinery is dysregulated by tumor-driver oncogenes. Here we give an overview of some natural compounds identified as CDK inhibitors with reported activity also against CDK9, that were taken as a model for the development of highly active synthetic anti-CDK9 agents. After, we summarize the data on CDK9 inhibition in a group of rare pediatric solid tumors such as rhabdomyosarcoma, Ewing’s sarcoma, synovial sarcoma and malignant rhabdoid tumors (soft tissue sarcomas), highlighting the more recent results in this field. Finally, we discuss the perspective and challenge of CDK9 modulation in cancer. |
format | Online Article Text |
id | pubmed-7438590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74385902020-09-03 CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas Cassandri, Matteo Fioravanti, Rossella Pomella, Silvia Valente, Sergio Rotili, Dante Del Baldo, Giada De Angelis, Biagio Rota, Rossella Mai, Antonello Front Pharmacol Pharmacology Cyclin-Dependent Kinases (CDKs) are well-known reliable targets for cancer treatment being often deregulated. Among them, since the transcription-associated CDK9 represents the sentry of cell transcriptional homeostasis, it can be a valuable target for managing cancers in which the transcriptional machinery is dysregulated by tumor-driver oncogenes. Here we give an overview of some natural compounds identified as CDK inhibitors with reported activity also against CDK9, that were taken as a model for the development of highly active synthetic anti-CDK9 agents. After, we summarize the data on CDK9 inhibition in a group of rare pediatric solid tumors such as rhabdomyosarcoma, Ewing’s sarcoma, synovial sarcoma and malignant rhabdoid tumors (soft tissue sarcomas), highlighting the more recent results in this field. Finally, we discuss the perspective and challenge of CDK9 modulation in cancer. Frontiers Media S.A. 2020-08-13 /pmc/articles/PMC7438590/ /pubmed/32903585 http://dx.doi.org/10.3389/fphar.2020.01230 Text en Copyright © 2020 Cassandri, Fioravanti, Pomella, Valente, Rotili, Del Baldo, De Angelis, Rota and Mai http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Cassandri, Matteo Fioravanti, Rossella Pomella, Silvia Valente, Sergio Rotili, Dante Del Baldo, Giada De Angelis, Biagio Rota, Rossella Mai, Antonello CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas |
title | CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas |
title_full | CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas |
title_fullStr | CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas |
title_full_unstemmed | CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas |
title_short | CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas |
title_sort | cdk9 as a valuable target in cancer: from natural compounds inhibitors to current treatment in pediatric soft tissue sarcomas |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438590/ https://www.ncbi.nlm.nih.gov/pubmed/32903585 http://dx.doi.org/10.3389/fphar.2020.01230 |
work_keys_str_mv | AT cassandrimatteo cdk9asavaluabletargetincancerfromnaturalcompoundsinhibitorstocurrenttreatmentinpediatricsofttissuesarcomas AT fioravantirossella cdk9asavaluabletargetincancerfromnaturalcompoundsinhibitorstocurrenttreatmentinpediatricsofttissuesarcomas AT pomellasilvia cdk9asavaluabletargetincancerfromnaturalcompoundsinhibitorstocurrenttreatmentinpediatricsofttissuesarcomas AT valentesergio cdk9asavaluabletargetincancerfromnaturalcompoundsinhibitorstocurrenttreatmentinpediatricsofttissuesarcomas AT rotilidante cdk9asavaluabletargetincancerfromnaturalcompoundsinhibitorstocurrenttreatmentinpediatricsofttissuesarcomas AT delbaldogiada cdk9asavaluabletargetincancerfromnaturalcompoundsinhibitorstocurrenttreatmentinpediatricsofttissuesarcomas AT deangelisbiagio cdk9asavaluabletargetincancerfromnaturalcompoundsinhibitorstocurrenttreatmentinpediatricsofttissuesarcomas AT rotarossella cdk9asavaluabletargetincancerfromnaturalcompoundsinhibitorstocurrenttreatmentinpediatricsofttissuesarcomas AT maiantonello cdk9asavaluabletargetincancerfromnaturalcompoundsinhibitorstocurrenttreatmentinpediatricsofttissuesarcomas |